Clinical trials: in Gabon
Malaria Transmission
Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity
Assessing the effect of neglected tropical diseases on Plasmodium falciparum transmission in an area of co endemicity.
- Trial name
- TRANSMAL (NCT02769013)
- Testing
- Pre-treatment follow up, S. haematobium treatment, Post treatment follow up
- Where
- 2 sites in Gabon, Ghana
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Malaria, Malaria Vaccines
Epidemiology Study of Malaria Transmission Intensity in Africa
The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).
- Trial name
- NCT01190202
- Testing
- Blood sampling, Assessment of body temperature
- Where
- 8 sites in Burkina Faso, Gabon and 4 more
- Volunteers
- 21,618 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Testing, Performance
Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections.
Malaria, schistosomiasis and ancylostomiasis are three parasitic diseases which affect hundreds of millions of people and are an important cause of global mortality and morbidity.
- Conditions
- Testing, Performance, Specificity, Sensitivity
- Trial name
- INSPiRED-WP3 (NCT04505046)
- Where
- Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Schistosomiasis Haematobia
Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection
Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is…
- Trial name
- SACT (NCT04264130)
- Testing
- Artesunate-Pyronaridine, Artemether-Lumefantrine, Artefenomel-Ferroquine
- Where
- Gabon
- Volunteers
- 54 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Malaria
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.
- Trial name
- NCT00866619
- Testing
- Malaria Vaccine 257049, Meningococcal C Conjugate Vaccine, Cell-culture rabies vaccine
- Where
- 10 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 15,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria,Falciparum
Cohort Event Monitoring Study of Pyramax®
The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes.
- Trial name
- NCT03201770
- Testing
- pyronaridine artesunate
- Where
- 5 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 8,572 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Missed Abortion, Pregnancy
Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial
The purpose of the proposed study is to compare - in a randomized, placebo-controlled, double-blinded trial - a combination of mifepristone and misoprostol to misoprostol used alone for missed abortion.
- Trial name
- NCT02342002
- Testing
- Mifepristone, Misoprostol
- Where
- 4 sites in Argentina, Gabon and 2 more
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sickle Cell Anemia, Sickle Cell Disease
Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose
The CADRE study is a multinational observational cohort of patients with sickle-cell disease (SCD) in five west and central sub-Saharan African countries.
- Trial name
- CADRE (NCT03114137)
- Where
- 13 sites in Cameroon, Côte d’Ivoire and 4 more
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Cardiologie et Développement
Acute Coronary Syndrome, Heart Failure
A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
FEVRIER study is an observatory of hospitalizations in cardiology units in sub-Saharan Africa.
- Conditions
- Acute Coronary Syndrome, Heart Failure, Syncope, Stroke
- Trial name
- FEVRIER (NCT03231449)
- Testing
- observation of current care
- Where
- 20 sites in Benin, Burkina Faso and 11 more
- Volunteers
- 5,000 people
- Sponsor
- Cardiologie et Développement
Hookworm Infection, Hookworm Disease
Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults
Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus hookworm life cycle that are thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source.
- Trial name
- NCT02126462
- Testing
- Na-APR-1 (M74)/Alhydrogel®, Na-GST-1/Alhydrogel®, Hepatitis B vaccine
- Where
- Gabon
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Malaria
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
GSK Biologicals is developing a number of candidate malaria vaccines for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00307021
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Where
- Gabon
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Uncomplicated Plasmodium Falciparum Malaria
Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.
A randomised, double-blind single-dose study to determine the efficacy, safety, tolerability and pharmacokinetics of OZ439 (artefenomel) in combination with piperaquine (PQP) in patients > 0.5 years and <= 70 years of age with…
- Trial name
- NCT02083380
- Testing
- Artefenomel 800mg: piperaquine 640mg, Artefenomel 800mg: piperaquine 960mg, Artefenomel 800mg: piperaquine 1440mg
- Where
- 9 sites in Benin, Burkina Faso and 5 more
- Volunteers
- 448 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria
Malaria is a protozoan infection transmitted by anopheline mosquitoes. The most severe forms are caused by Plasmodium (P) falciparum and to a much lesser extent by P. vivax.
- Trial name
- REPLAMO (NCT02528279)
- Testing
- Coartem
- Where
- 2 sites in Gabon
- Volunteers
- 50 people
- Sponsor
- Albert Schweitzer Hospital
Plasmodium Falciparum Malaria, Malaria
Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge
The study is designed to establish infectivity of Plasmodium falciparum sporozoites (PfSPZ) via intravenous (IV) administration in three groups with different malaria immunity-status: 1.
- Trial name
- NCT02237586
- Testing
- PfSPZ Challenge
- Where
- Gabon
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Immune Reconstitution Inflammatory Syndrome, Opportunistic Infections
Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
The objective of this project is to determine clinical and biological predictors of Immune Reconstitution Inflammatory Syndrome (IRIS) occurrence in HIV infected patients who are started on antiretroviral therapy (ART), and to…
- Trial name
- IRIS (NCT01557803)
- Where
- Gabon
- Volunteers
- 107 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pregnancy, Malaria
Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy
The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the prevention of malaria effects on the mother and…
- Conditions
- Pregnancy, Malaria, HIV Infections
- Trial name
- MiPPAD (NCT00811421)
- Testing
- Sulphadoxine-pyrimethamine, Mefloquine (full dose), Mefloquine (split dose)
- Where
- 5 sites in Benin, Gabon and 3 more
- Volunteers
- 5,820 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
HIV Infection, Tuberculosis
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
This study investigates the prevention of early mortality in patients initiating antiretroviral therapy (ART) in sub-Saharan Africa where 79% of the co-infected cases of TB reside.
- Trial name
- PrOMPT (NCT01417988)
- Testing
- Experimental: Empiric TB treatment, ART only arm
- Where
- 3 sites in Gabon, Mozambique and 1 more
- Volunteers
- 44 people
- Sponsor
- Prof JMA Lange
Fever, Malaria
Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children
The main objective is to compare the safety and efficacy of 4 artemisinin-based combinations (ACT) [amodiaquine-artesunate (AQ+AS), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and chlorproguanil/dapsone…
- Trial name
- NCT00393679
- Testing
- amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL)
- Where
- 8 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 4,112 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Blood Pressure
Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial
The purpose of this study is to compare the blood pressure lowering efficacy of a treatment regimen based on a dihydropyridine calcium-channel blocker combined with an angiotensin II type-1 receptor blocker with the recommended…
- Trial name
- NOAAH (NCT01030458)
- Testing
- amlodipine 5/10 mg per day plus valsartan 160 mg/day, hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
- Where
- 7 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 183 people
- Sponsor
- KU Leuven